Interconversion of functional activity by minor structural alterations in nonpeptide AT2 receptor ligands

ACS Medicinal Chemistry Letters

Volumn 6, Issue 2, 2015, Pages 178-182

  Wallinder, Charlotta ^a   Sköld, Christian ^a   Botros, Milad ^a   Guimond, Marie Odile ^b   Hallberg, Mathias ^a   Gallo Payet, Nicole ^b   Karlén, Anders ^a   Alterman, Mathias ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

agonist; antagonist; AT2 receptor; C21 M024; C38 M132; nonpeptide ligands

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN DERIVATIVE; BIPHENYL DERIVATIVE; CARBENE; IMIDAZOLE DERIVATIVE; M 024; M 132; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; LIGAND BINDING; NEURITE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 84922879972     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500427r     Document Type: Article

References (28)

1. Tamargo, J.; López-Sendón, J. Novel therapeutic targets for the treatment of heart failure Nat. Rev. Drug Discovery 2011, 10, 536-555
2. Foulquier, S.; Steckelings, U. M.; Unger, T. Perspective: A tale of two receptors Nature 2013, 493, S9
3. Rice, A. S. C.; Dworkin, R. H.; McCarthy, T. D.; Anand, P.; Bountra, C.; McCloud, P. I.; Hill, J.; Cutter, G.; Kitson, G.; Desem, N.; Raff, M. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial Lancet 2014, 383, 1637-1647
4. 2 receptor agonist J. Med. Chem. 2004, 47, 5995-6008
5. 2 receptor agonists: Arylbenzylimidazole structure-activity relationships J. Med. Chem. 2006, 49, 7160-7168
6. 2 receptor agonists devoid of the imidazole ring system Bioorg. Med. Chem. 2007, 15, 7166-7183
7. 2 receptor-a matter of love and hate Peptides 2005, 26, 1401-9
8. 2 receptors: beneficial counter-regulatory role in cardiovascular and renal function Pflugers Arch. Eur. J. Physiol. 2013, 465, 99-110
9. 1 receptors J. Biol. Chem. 1996, 271, 22729-22735
10. Kaschina, E.; Grzesiak, A.; Li, J.; Foryst-Ludwig, A.; Timm, M.; Rompe, F.; Sommerfeld, M.; Kemnitz, U. R.; Curato, C.; Namsolleck, P.; Tschope, C.; Hallberg, A.; Alterman, M.; Hucko, T.; Paetsch, I.; Dietrich, T.; Schnackenburg, B.; Graf, K.; Dahlof, B.; Kintscher, U.; Unger, T.; Steckelings, U. M. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008, 118, 2523-2532
11. 2 receptor Curr. Hypertens. Rep. 2013, 15, 25-30
12. Lauer, D.; Slavic, S.; Sommerfeld, M.; Thöne-Reineke, C.; Sharkovska, Y.; Hallberg, A.; Dahlöf, B.; Kintscher, U.; Unger, T.; Steckelings, U. M.; Kaschina, E. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart Hypertension 2014, 63, e60-e67
13. 2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage J. Hypertens. 2009, 27, 2444-2451
14. 2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer Prostate 2013, 73, 1057-1068
15. 2 receptor agonist to structurally related antagonists J. Med. Chem. 2012, 55, 2265-2278
16. 2) receptor. Effects on neurite outgrowth in NG108-15 cells Eur. J. Pharmacol. 2013, 699, 160-171
17. 1 ligands: susceptibility to receptor mutations Mol. Pharmacol. 1997, 51, 301-311
18. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists J. Comput.-Aided Mol. Des. 1993, 7, 83-102
19. SYBYL 7.3; Tripos International: St. Louis, MO.
20. 2 receptor agonists: Benzamide structure-activity relationships Bioorg. Med. Chem. 2008, 16, 6841-6849
21. 1 receptors are down-regulated during gestation Clin. Exp. Pharmacol. Physiol. 1997, 24, 309-14
22. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella, J. B. I.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S.-E.; Timmermans, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N -(biphenylylmethyl)imidazoles as potent, orally active antihypertensives J. Med. Chem. 1991, 34, 2525-2547
23. 2 receptor modulates T-type calcium current in non-differentiated NG108-15 cells FEBS Lett. 1992, 309, 161-4
24. 2 receptor in PC12W cells Regul. Pept. 1993, 44, 207-213
25. 2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors J. Biol. Chem. 1996, 271, 22729-35
26. ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells Mol. Endocrinol. 1999, 13, 1615-26
27. Gendron, L.; Coté, F.; Payet, M. D.; Gallo-Payet, N. Nitric oxide and cyclic GMP are involved in angiotensin II AT(2) receptor effects on neurite outgrowth in NG108-15 cells Neuroendocrinology 2002, 75, 70-81
28. Khosla, M. C.; Leese, R. A.; Maloy, W. L.; Ferreira, A. T.; Smeby, R. R.; Bumpus, F. M. Synthesis of some analogs of angiotensin II as specific antagonists of the parent hormone J. Med. Chem. 1972, 15, 792-5